ArticleThe Lancet regional health. Western Pacific2024

Zuberitamab, an innovative anti-CD20 monoclonal antibody, for patients with primary immune thrombocytopenia in China: a randomized, double-blind, placebo-controlled, phase 2 study.

Min Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.